Activated protein C resistance: The most common risk factor for venous thromboembolism

Journal of the American Board of Family Practice

Volumn 13, Issue 2, 2000, Pages 111-115

  Sheppard, Dawn R ^a  

^a US Gen Leonard Wood Army Hosp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ACTIVATED PROTEIN C RESISTANCE; DIFFERENTIAL DIAGNOSIS; GENETICS; GENOTYPE; HUMAN; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ANTICOAGULANTS; DIAGNOSIS, DIFFERENTIAL; GENOTYPE; HUMANS; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0034153611     PISSN: 08938652     EISSN: None     Source Type: Journal    
DOI: 10.3122/15572625-13-2-111     Document Type: Article

References (23)

1. Bridgen ML. The hypercoagulable state. Who, how, and when to test and treat. Postgrad Med 1997;101: 249-52, 254-62, passim.
2. Dahlback B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to GLn mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost 1995;74:139-48.
3. Dahlback B. Resistance to activated protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons. Thromb Haemost 1995;73: 739-42.
4. Dahlback B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994;94:923-7.
5. Hainaut P, Azerad MA, Lehmann E, et al. Prevalence of activated protein C resistance and analysis of clinical profile in thromboembolic patients. A Belgian prospective study. J Intern Med 1997;241:427-33.
6. Dahlback B, Carlsson M, Svensson P. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
7. Zoller B, Hillarp A, Berntorp E, Dahlback B. Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. Annu Rev Med 1997;48:45-58.
8. Hillarp A, Zoller B, Dahlback B. Activated protein C resistance as a basis for venous thrombosis. Am J Med 1996;101:534-40.
9. Chrobak L, Dulicek P. Resistance to activated protein C as pathogenic factor of venous thromboembolism. Acta Medica (Hradec Kralove)1996;39:55-62.
10. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-22.
11. Dahlback B. Factor V And protein S as cofactors to activated protein C. Haematologica 1997;82:91-5.
12. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369: 64-7.
13. Harris JM, Abramson N. Evaluation of recurrent thrombosis and hypercoagulability. Am Fam Physician 1997;56:1591-6, 1601-2.
14. Samama MM, Simon D, Horellou MH, Trossaert M, Elalamy I, Conard J. Diagnosis and clinical characteristics of inherited activated protein C resistance. Haemostasis 1996;26:315-30.
15. Rees D, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
16. Florell SR, Rodgers GM. inherited thrombotic disorders: an update. Am J Hematol 1997;54:53-60.
17. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. JAMA 1997;277:1305-7
18. Girolami A, Simioni P, Scarano L, Girolami B. Venous and arterial thrombophilia. Haematologica 1997;82:96-100.
19. Levesque H, Courtois H. [Estrogen therapy and venous thromboembolic disease]. Rev Med Interne 1997;18(Suppl 6):S620-5.
20. Barlow DH. HRT and the risk of deep vein thrombosis. Int J Gynaecol Obstet 1997;59(Suppl 1):S29-33.
21. Griffin JH, Heeb MJ, Kojima Y, et al. Activated protein C resistance: molecular mechanisms. Thromb Haemost 1995;74:1:444-8.
22. Ruiz-Arguelles GJ, Garces-Eisele J, Alarcon-Segovia D, Ruiz-Arguelles A. Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome. Blood Coagul Fibrinolyis 1996;7:344-8.
23. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996;335:1816-28.